Spt3 of Saccharomyces cerevisiae is a factor required for normal transcription from particular RNA polymerase II-dependent promoters. Previous genetic and biochemical analyses have shown that Spt3 interacts with the yeast TATA-binding protein (TBP). To identify other factors that might interact with Spt3, we have screened for mutations that, in combination with an spt3 null mutation, lead to inviability. In this way, we have identified a mutation in MOT1, which encodes an ATP-dependent inhibitor of TBP binding to TATA boxes. Previous analyses suggested that Mot1 causes repression in vivo. However, our analysis of mot1 mutants shows that, similar to spt3 mutants, they have decreased levels of transcription from certain genes, suggesting that Mot1 may function as an activator in vivo. In addition, mot1 mutants have other phenotypes in common with spt3⌬ mutants, including suppression of the insertion mutation his4-912␦. Motivated by these Spt3-Mot1 genetic interactions, we tested for genetic interactions between Spt3 and the general transcription factor TFIIA. TFIIA has been shown previously to be functionally related to Mot1. We found that overexpression of TFIIA partially suppresses an spt3⌬ mutation, that toa1 mutants have Spt ؊ phenotypes, and that spt3⌬ toa1 double mutants are inviable. We believe that, taken together, these data suggest that Spt3, Mot1, and TFIIA cooperate to regulate TBP-DNA interactions, perhaps at the level of TATA box selection in vivo.
For transcription initiation by RNA polymerase II, binding of the TATA-binding protein (TBP) to the TATA element is believed to be one of the central rate-limiting steps in the formation of a functional RNA polymerase II preinitiation complex (6) . Studies in vitro have shown that TBP is able to bind with similar affinities to a number of TATA and TATAlike sequences (22) . However, evidence in vivo suggests that not all TATA boxes are utilized similarly and that the promoter context influences the function of the TATA box (57a, 59) . Furthermore, some promoters, such as the CYC1 and GAL1 promoters, have been shown to differ with respect to the occupancy of the TATA box in the inactive state (5, 8, 53) . It is unresolved how, in vivo, promoter context and TBP-interacting factors influence different aspects of TBP function, such as TATA box association and dissociation rates.
Several studies have led to the identification of positive regulatory factors that promote stability of the TBP-DNA complex. Among these is the general transcription factor TFIIA, which can stabilize TBP binding to the TATA box in the presence of TBP inhibitors and under suboptimal conditions in vitro (12, 26) . Recent evidence from in vivo studies with Saccharomyces cerevisiae and from highly purified in vitro systems in Drosophila melanogaster suggests that TFIIA can stimulate both activated and basal transcription and may associate with other TBP-associated factors (TAFs) (29, 56, 68) . In addition to TFIIA, several studies suggest that TBP-TATA interactions are controlled by certain upstream activators (7, 31, 32, 57, 66) . It has also been shown that one function of TAFs in activated transcription is to cooperate with upstream activators to stabilize the TBP-TAF-TFIIA complex (33) . Thus, TBP and the TBP-DNA complex are likely to be the targets of multiple factors to control normal transcription in vivo.
In contrast to activities that promote the TBP-TATA box interaction, a number of negative factors that destabilize this interaction have been identified. Several of these TBP inhibitors, such as the HeLa factors Dr1/NC2␤, Dr2/TopoI, and NC1, have been purified on the basis of their ability to repress basal transcription in vitro (27, 36, 37, 39, 67) . Analysis of Dr1/NC2␤ suggests that it interacts with another factor, DRAP1/NC2␣, to repress transcription by interacting with TBP and excluding the general transcription factors TFIIA and TFIIB, thus precluding the formation of a functional preinitiation complex (21, 30, 40, 67) . The in vivo roles of these TBP inhibitors have yet to be determined. However, the existence of these factors suggests that there may be interactions with either DNA or other factors that must be prevented under physiological conditions in order for transcription to occur.
The yeast TBP inhibitor Mot1 has been proposed to block TBP function in a manner distinct from those of Dr1, Dr2, and NC1. Mot1 was identified in vitro in two ways. First, Mot1 was purified on the basis of its ability to remove TBP from TATA boxes in an ATP-dependent fashion (2, 3) . In these studies, levels of in vitro basal transcription from mot1 mutant extracts were higher than levels from wild-type extracts, consistent with a negative role for Mot1. Second, Mot1 was identified as a yeast TAF that exists in a TBP complex distinct from TFIID, the TBP complex that contains the core yeast TAFs (46, 47) . Mutations in MOT1 were identified on the basis of their ability to increase transcription from a number of unrelated RNA polymerase II-dependent promoters (13, 44) . Recent work has also suggested that Mot1 is required for repression by Leu3 in vitro and in vivo (60). Since Mot1 activity is counteracted by the general transcription factor TFIIA in vitro, it has been proposed that the balance of TFIIA and Mot1 activities regulate TBP-TATA box interactions (2, 3) .
Several other factors identified genetically in yeast are also thought to control TBP function in vivo. These factors were identified by mutations that suppress the transcriptional defects caused by insertions of Ty or solo ␦ elements in the promoters of the HIS4 and LYS2 genes (19, 61, 64, 65) . These genes were designated SPT for suppressor of Ty. Mutations in SPT15, which encodes TBP, were originally isolated in this manner (17) . Another factor, Spt3, is a nonessential, nuclear protein that has been proposed to regulate TBP-TATA interactions in vivo (15, 64) . Mutations in SPT3 cause mutant phenotypes similar to those caused by particular mutations in SPT15, including slow growth, mating defects, sporulation defects, and suppression of similar Ty and solo ␦ insertion mutations (17, 65) . Analysis of transcription in spt3⌬ mutants has shown that Spt3 is required for transcription of particular RNA polymerase II-dependent genes (24, 65) . Moreover, genetic and biochemical analysis of Spt3 has shown that Spt3 interacts with TBP (15) . Recently, Spt3 has been shown to be 26% identical to human TAF II 18 and 21% identical to another yeast factor of unknown function, Fun81 (14, 38) . Taken together, the genetic and biochemical data suggest that Spt3 is a TAF required for TBP function at certain promoters.
To identify factors that are functionally related to Spt3, we have screened for mutations that cause lethality in combination with an spt3 null mutation (spt3⌬ synthetic lethal mutations). This screen identified a mutation in MOT1 as an spt3⌬ synthetic lethal mutation. Further characterization has shown that mot1 mutants and spt3⌬ mutants possess some common phenotypes, including decreased levels of certain transcripts. This result suggests that, in contrast to previous models, Mot1 functions as a positive regulatory factor in the transcription of certain genes in vivo. In addition, we have found multiple genetic interactions between TFIIA and SPT3, suggesting that these factors may perform functionally similar roles in the regulation of TBP function. These data suggest that Spt3, Mot1, and TFIIA are functionally related and that together they may regulate promoter-specific TBP-DNA interactions.
MATERIALS AND METHODS
Yeast strains and genetic methods. The yeast strains used (Table 1) are derived from an S288C GAL2 ϩ derivative (63) and were constructed by standard methods (51) . All spt mutations used in this study have been described previously (15, 23, 65) . The mot1-1 allele (13) and the mot1-1033 allele (44) have been described previously, and the mot1-24 allele was isolated in this study. Integration of the mot1-1 mutation into an S288C background was done by standard procedures with plasmid pJM75. The toa1-18GSG allele has been described previously (29) . The ste12⌬ strains FY1216, FY1217, and FY1218 were constructed by standard methods in an S288C background with the plasmid pLG36. Determination of synthetic lethality was done as described in Table 3 , footnote a. Yeast strains were transformed by a lithium acetate procedure (18) . Standard methods of mating, sporulation, and tetrad analysis were used (51) .
Media. Rich (YPD), minimal (SD), synthetic complete (SC) media containing 5-fluoroorotic acid (5-FOA) and sporulation media were prepared as described previously (51) . Suppression of insertion mutations was scored on SD medium supplemented with particular nutrients or on SC medium lacking appropriate nutrients. Yeast transformants were selected on the appropriate SC media.
DNA preparation and analysis. Escherichia coli HB101 and DH5␣ were used as hosts for plasmids (52) . Plasmids were constructed, maintained, and isolated by standard methods (52) . Plasmids were recovered from yeast as described previously (50) . Restriction enzymes and DNA-modifying enzymes were purchased from New England Biolabs (Beverly, Mass.) and Boehringer Mannheim Biochemicals (Indianapolis, Ind.) and used as recommended by the manufacturer.
Plasmids. The pRS series of vectors has been described previously (9, 54) . pJM75 contains the XhoI-NotI fragment of pJM81 subcloned into pRS306. pJM89 contains the XhoI-NotI MOT1 fragment from pRS7.1BglII (13) subcloned into the XhoI-NotI sites of pRS314. pJM64 is pRS316 with the BstXI polylinker site eliminated. pJM65 contains the XhoI-NotI MOT1 fragment from pRS7.1 BglII (13) subcloned into the XhoI-NotI sites of pJM64. pJM118 has the EcoRI TOA2-containing fragment from pSH325 (TOA2 in pRS316, generously provided by S. Hahn) subcloned into the EcoRI site of pRS426. pJM120 has the EcoRI-NotI TOA1-containing fragment from pSH342 (TOA1 in pRS316, generously provided by S. Hahn) subcloned into the EcoRI-NotI sites of pRS426. pJM122 has the EcoRI TOA2-containing fragment from pSH325 subcloned into the EcoRI site of pJM120. pLG36 is ste12⌬::LEU2 in pRS306.
Plasmids used for Northern probes were pFW45 (HIS4) (62), pB161 (Ty1) (62), pJEH122 (DED1) (25) , pAB510 (STE2) (generously provided by G. Sprague), pHB59 (TPI1) (generously provided by H. Baker), pSM39 (MFa1) (41), pSM29 (MFa2) (41), pYST138 (TUB2) (55), pRS7.1BglII (MOT1) (13) , and pCC1 (SPT3) (10) .
DNA sequence analysis. For sequencing portions of both wild-type and mutant MOT1 genes, the appropriate restriction fragments were first subcloned into pRS316. Sequencing was performed by a protocol provided by the Sequenase version 2.0 kit from U.S. Biochemical Corp. Synthetic primers and M13 universal and reverse primers were used to determine sequences on both strands. The sequence was analyzed by using the BLAST program (1) and compared against known sequences and proteins in the GenBank, EMBL, and PIR databases. RNA preparation and Northern hybridization analysis. Cells for RNA isolation were grown at 30ЊC in supplemented SD medium to a density of 1 ϫ 10 7 to 2 ϫ 10 7 cells/ml. Total RNA was isolated by a hot-phenol method (4). Northern transfer and hybridizations were performed as described previously (58) . 32 Plabeled probes were generated either with a Boehringer Mannheim Biochemical nick translation kit or by random hexamer labeling (4). Northern blots were quantitated on a Molecular Dynamics PhosphorImager.
Screen for strains carrying spt3⌬ synthetic lethal mutations. An spt3⌬ strain, FY51, was transformed with pCC1, an SPT3 CEN URA3 plasmid. This strain was mutagenized with ethyl methanesulfate by standard methods (4) . Mutagenized cells were plated on YPD and incubated at 30ЊC. Approximately 15,000 colonies were screened for the inability to grow without pCC1 by replica plating to 5-FOA plates. Those colonies that did not grow on 5-FOA but did grow on SC-Ura and SC were chosen for further study. To demonstrate that a single gene in conjunction with an spt3⌬ mutation was responsible for the synthetic lethality, 5-FOAsensitive progeny were crossed to FY51 and sporulated, and spores from tetrad dissection were screened for 5-FOA sensitivity. 5-FOA sensitivity was shown to segregate 2:2. 5-FOA-sensitive double mutants were crossed to a wild-type strain, FY41, to isolate the new mutation in an SPT3 background. These single mutations were verified to cause synthetic lethality with an spt3⌬ mutation by crossing each candidate to FY51 containing pCC1 and reconstructing the synthetic lethality by loss of the plasmid. Mutations that reconstructed the synthetic lethality were chosen for further study.
Cloning of mot1 mutations and sequencing of the mot1-24 mutation. The mot1-24 mutation was localized by gap repair (43) . Plasmid pRS7.1BglII was gapped with different restriction enzymes. Each gapped plasmid was transformed into FY1210, and the resulting Ura ϩ transformants were screened for a Ts phenotype. An NruI-EcoNI gapped plasmid resulted in all Ts Ϫ transformants, indicating that the mot1-24 mutation was in this region. The plasmid was rescued from yeast, and the NruI-EcoNI fragment was subcloned into pJM89 (MOT1 in pRS314) to create pJM77. pJM77 was shown to carry the mutation by introducing it into FY1215, a mot1⌬2::LEU2 strain, by plasmid shuffle. The plasmid supported viability but caused a Ts Ϫ phenotype. The NruI-EcoNI fragment from both a mot1-24 mutant and a MOT1 plasmid was sequenced on both strands. We identified a single difference between the mot1-24 and MOT1 sequences. The mot1-24 mutation altered nucleotide 4769 of the published sequence (13), resulting in a predicted arginine-to-lysine change at codon 1507.
The mot1-1 mutation was cloned based on information generously provided by Jeremy Thorner. pJM65 was digested with HpaI and BstXI and used to transform the mot1-1 strain JD215b to Ura ϩ . Following transformation to Ura ϩ , the mot1-1 mutation cloning proceeded as described for the mot1-24 mutation cloning.
RESULTS
Isolation of mutations that cause lethality with an spt3⌬ mutation. To identify factors that are functionally related to Spt3, we screened for mutations that in combination with an spt3⌬ mutation cause inviability (spt3⌬ synthetic lethal mutations). From this analysis two spt3⌬ synthetic lethal mutations were identified. One of these mutations is in the previously identified PTA1 gene (34, 42) . The second mutation was shown to be in the MOT1 gene as described below. Studies arising from the discovery of the mot1-24 spt3⌬ synthetic lethality comprise the remainder of this report. mot1-24 causes synthetic lethality with an spt3⌬ mutation. To identify the gene corresponding to this second synthetic lethal mutation, the gene was cloned by complementation of two recessive phenotypes: slow growth at 30ЊC and Ts Ϫ at 37ЊC. A single plasmid that fully complemented the slowgrowth phenotype at 30ЊC and partially complemented the Ts Ϫ phenotype at 37ЊC was identified. Sequencing of a portion of the plasmid insert revealed that it contained the MOT1 gene. A plasmid containing only MOT1, pRS7.1BglII (13) , showed the same complementation as the original library plasmid.
To prove that a mutation in mot1 had been isolated, we performed several tests. First, complementation analysis showed that mot1-24 fails to complement two other Ts Ϫ mot1 mutations, mot1-1 (13) and mot1-1033 (44) , for growth at 37ЊC. Second, tetrad analysis of mot1-1/mot1-24 and the mot1-1033/ mot1-24 heterozygotes showed Ts ϩ :Ts Ϫ segregation of 0:4 in 40 tetrads for each cross. Therefore, mot1-24 is very tightly linked to two other mot1 mutations. Finally, gap rescue and sequence analysis of the mot1-24 mutation (see Materials and Methods) revealed a single-base-pair change in the mot1-24 open reading frame, resulting in a predicted arginine-to-lysine change at codon 1507 of MOT1. Taken together, these results demonstrate that a mutation in MOT1, mot1-24, causes lethality in combination with an spt3⌬ mutation. The synthetic lethal phenotype of a mot1-24 spt3⌬ strain is shown in Fig. 1 .
MOT1 mRNA levels are not significantly altered in an spt3⌬ mutant. One possible explanation for the mot1-24 spt3⌬ synthetic lethality would be that Spt3 controls MOT1 transcription. By this model, mot1-24 spt3⌬ lethality would be the result of a greater reduction in the essential function of Mot1 due to the combination of a mutation in MOT1 and a reduction in its transcription caused by an spt3⌬ mutation. To test this hypothesis, we examined MOT1 mRNA levels in SPT3 ϩ and spt3⌬ strains by Northern blotting. As shown in Fig. 2 , MOT1 mRNA levels were not significantly decreased in an spt3⌬ strain, being within twofold of the levels in an SPT3 ϩ strain. This result suggests that the synthetic lethality observed in spt3⌬ mot1-24 double mutants is not caused by Spt3 control of MOT1 mRNA levels. VOL. 17, 1997 Spt3, Mot1, AND TFIIA GENETIC INTERACTIONSrelated, we tested if mot1 mutants and spt3 mutants have any common phenotypes. Previous work has shown that an spt3⌬ mutation suppresses Ty and solo ␦ insertion mutations in the HIS4 and LYS2 5Ј regions (64) . We tested mot1-1 and mot1-24 mutants for suppression of the solo ␦ insertion mutation his4-912␦. Our results show that both mot1 mutations strongly suppress his4-912␦ (Fig. 3) . The fact that two different mot1 mutants have an Spt Ϫ phenotype suggests that this phenotype is not allele specific. Recently, in a separate study, other mot1 mutations were shown to suppress a derivative of his4-912␦ (28) . However, mot1-1 and mot1-24 mutations fail to suppress a different insertion mutation, his4-917␦, that is suppressed by an spt3⌬ mutation (data not shown). In addition, spt3⌬ mutants have mating defects that have been correlated with decreased levels of mRNAs for the three major mating factor genes, MF␣1, MFa1, and MFa2 (24) . Analysis of mating showed that both mot1-1 and mot1-24 mutants do not have detectable mating defects (data not shown). Thus, mot1 mutant phenotypes overlap with but are not identical to spt3⌬ phenotypes.
Analysis of mot1-1 spt3⌬ and mot1-1033 spt3⌬ double mutants. To determine if the lethality of the mot1-24 spt3⌬ double mutation is allele specific with respect to MOT1, double mutants carrying spt3⌬ and one of two other mot1 alleles, mot1-1 and mot1-1033 were constructed. At 30ЊC, both the mot1-1 spt3⌬ and mot1-1033 spt3⌬ double mutants are alive but grow more slowly than any of the single mutants ( Table 2 ). The growth of these double mutants correlates with the growth of the single mot1 mutants at 30ЊC, where the mot1 mutants range from fastest to slowest growth as follows: mot1-1033 Ͼ mot1-1 Ͼ mot1-24 (data not shown). Since spt3⌬ mutations do not show synthetic lethality or sickness with other spt mutations that cause poor growth (15, 62, 65) , the spt3⌬ mot1 synthetic phenotype suggests that both proteins contribute in a nonredundant fashion toward a common, essential function. mot1 mutations cause reduced levels of certain transcripts. It has been previously shown, both in vivo (13, 44) and in vitro (3) , that mot1 mutations cause increased levels of transcripts from a number of unrelated RNA polymerase II-dependent genes. Since mot1 mutations cause an Spt Ϫ phenotype, we examined their effects on a set of transcripts that are reduced by an spt3⌬ mutation. Surprisingly, this analysis showed that both mot1-1 and mot1-24 mutations cause greatly decreased levels of both Ty and HIS4 mRNAs (Fig. 4A ) (6-to 10-fold decrease) and also cause a significant decrease in STE2 mRNA levels (3.2-fold decrease). Quantitation of the Northern blots by PhosphorImager analysis showed that the mRNA levels of all other genes tested (DED1, MFa1, MFa2, TPI1, and TUB2) were affected less than twofold. In the spt3⌬ strain we observed greatly decreased levels of Ty, MFa1, and MFa2 transcripts, as previously described for spt3⌬ mutants. Thus, spt3 and mot1 mutations cause decreases in a partially overlapping set of transcripts. We also analyzed mRNA levels in both mot1-1 and mot1-24 mutants after 1, 2, and 3 h of growth at 37ЊC and observed decreases similar to those seen in cells grown at 30ЊC (data not shown). Thus, in contrast to previous observations, mot1 mutations cause decreased levels of certain mRNAs.
The mot1-1 mutation was originally isolated as bypassing the requirement for the activator Ste12 (13). To determine if our mot1 mutants also had this phenotype, we analyzed the mRNA levels for two different Ste12-dependent genes in both ste12⌬ and STE12 ϩ backgrounds. Based on the previous results, we would expect that in a mot1 background the ste12⌬ defect would be partially suppressed. However, our results showed that ste12⌬ is not suppressed by mot1 mutations (Fig. 4B) 
a Growth of mot1 and mot1 spt3⌬ mutants. ϩ, strong growth; ϩ/Ϫ, weak growth; Ϫ/ϩ, very weak growth; Ϫ, no growth.
b Growth on YPD. c mot1 spt3⌬ double mutant combinations were scored for growth at 30ЊC on 5-FOA.
d Suppression of the his4-912␦ insertion allele was scored by comparing growth on minimal medium lacking and containing histidine. ϩ, no growth on minimal medium lacking histidine; Ϫ, indicates growth on minimal medium lacking histidine.
transcripts, Ty and MFa2. Thus, we did not observe the same effects on transcription that Davis et al. (13) observed in the mot1-1 mutant.
TFIIA overexpression partially suppresses spt3⌬. Several results strongly suggest that TFIIA and Mot1 are functionally related (2, 3) . In addition, in vitro experiments show that TFIIA can stabilize TBP binding to DNA, and it has been proposed that Spt3 might function to help TBP bind to TATA boxes (15) . Therefore, we tested if overexpression of TOA1 and TOA2, the yeast genes that encode the two subunits of TFIIA, could suppress an spt3⌬ mutation. We also tested for suppression of the spt15-21 mutation, which has been proposed to cause a defect in a functional interaction between TBP and Spt3 (15) . Suppression was examined by assaying the Spt Ϫ phenotype with respect to the insertion mutation lys2-173R2. In a wild-type background, lys2-173R2 strains are Lys ϩ , while in spt3⌬ or spt15-21 mutant backgrounds, this insertion causes a Lys Ϫ phenotype (17, 65) . The results demonstrated that overexpression of TFIIA suppresses both spt3⌬ and spt15-21 mutations (Fig. 5) . Both spt3⌬ and spt15-21 strains are Lys Ϫ in the absence of TFIIA overexpression; however, when TFIIA was overexpressed, both the spt3⌬ and the spt15-21 strains were Lys ϩ . Overexpression of either TOA1 or TOA2 alone fails to suppress spt3⌬ or spt15-21, suggesting that it is the increased level of functional TFIIA that is responsible for the suppression (data not shown). To test if overexpression of any other protein that binds to TBP can generally suppress spt3⌬ or spt15-21 mutations, we also overexpressed SUA7, which encodes TFIIB (45) . As shown in Fig.  5 , SUA7 overexpression does not suppress spt3⌬ or spt15-21 mutations. Finally, overexpression of SPT15 very weakly suppressed an spt3⌬ mutation (34, 48) . Taken together, these results strongly suggest that Spt3 and TFIIA are functionally related.
A toa1 mutant is Spt ؊ , and the mutation causes synthetic lethality with both an spt3⌬ mutation and mot1 mutations. Prompted by the TFIIA dosage suppression of an spt3⌬ mutation, we tested a toa1 mutation for Spt Ϫ phenotypes and for synthetic lethality with an spt3⌬ mutation and with mot1 mutations. To determine if toa1 mutants have Spt Ϫ phenotypes, we analyzed toa1-18GSG for suppression of the solo ␦ insertion mutations his4-912␦ and his4-917␦. toa1-18GSG was found to suppress his4-912␦ weakly at 30ЊC and strongly at 32ЊC; his4-917␦ was not suppressed (data not shown).
To test for synthetic lethality between toa1 and spt3⌬ mutations, we crossed the toa1-18GSG mutant with an spt3⌬ strain. Tetrad analysis demonstrated that the toa1-18GSG spt3⌬ double mutant is inviable (Table 3 ). Toa1 and Toa2 protein levels were unaffected in an spt3⌬ mutant compared to a wild-type strain (data not shown), suggesting that the toa1 spt3⌬ synthetic lethality is caused by the combined loss of both activities and not by an effect of spt3⌬ on TOA1 or TOA2 expression. To   FIG. 4 . mot1 mutations decrease transcription. (A) mRNA levels of the genes indicated at the left were examined in the wild-type strain and in mot1-1, mot1-24, and spt3⌬ mutants. The strains used were, from left to right, FY98, FY403, FY1214, and FY1216. Although the mot1-24 mutation appeared to cause a decrease in MFa1 message similar to that caused by spt3⌬, PhosphorImager analysis showed MFa1 message levels to be decreased less than twofold compared to the normalization probe. (B) mRNA levels in the wild-type strain and in mot1-1, mot1-24 and spt3⌬ mutants were analyzed in STE12 ϩ and ste12⌬ backgrounds. The strains used were, from left to right FY98, FY1217, FY403, FY822, FY1214, FY1219, FY1216, and FY1218. Total RNA was prepared from each strain and subjected to Northern analysis. Fifteen micrograms of RNA was run in each lane. The filter was hybridized with the probes listed at the left. After each successive hybridization, the filter was stripped and reprobed. The amount of RNA loaded in each lane varied by less than twofold as determined by normalization to TPI1 message. This figure was produced by using Adobe Photoshop and a Fujix Pictography 3000 printer.
VOL. 17, 1997 Spt3, Mot1, AND TFIIA GENETIC INTERACTIONScomplete the analysis of possible synthetic lethal relationships between SPT3, TOA1, and MOT1, we also tested for toa1 mot1 synthetic lethality. These results (Table 3) demonstrate that toa1-18GSG mot1-24mutants are also inviable. Thus, all double mutation combinations among spt3, toa1, and mot1 mutations cause synthetic lethality, and each mutation alone causes some Spt Ϫ phenotypes, strongly suggesting that the products of these genes are functionally related and may control similar aspects of TBP function.
DISCUSSION
In these studies we have demonstrated a functional relationship between Spt3, Mot1, and TFIIA. The connection between Spt3 and Mot1 comes from three lines of evidence. First, an spt3⌬ mutation causes lethality in combination with a mot1 mutation. Second, mot1 mutants have an Spt Ϫ phenotype. Third, mot1 mutations cause a significant decrease in the levels of Ty mRNA. The connection between Spt3 and TFIIA was investigated based on previous studies demonstrating an interaction between Mot1 and TFIIA. Our results show that overproduction of TFIIA suppresses some spt3⌬ mutant phenotypes, that toa1 mutants have Spt Ϫ phenotypes, and that spt3⌬ toa1 double mutants are inviable. Finally, we have shown that toa1 mot1 double mutants are also inviable. Taken together, these data (summarized in Fig. 6 ) suggest that Spt3, Mot1, and TFIIA work together to control promoter-specific TBP-TATA box interactions.
The identification of mot1 as an spt3⌬ synthetic lethal mutation has led us to the surprising result that mot1 mutations cause Spt Ϫ phenotypes and greatly decreased levels of both Ty and HIS4 transcripts. In contrast, previous analyses showed that mot1 mutations increased transcription in vivo and in vitro (3, 13, 44) . In those studies only one gene, an MFa2-lacZ fusion, showed a modest (twofold) decrease (3). We also observed a modest decrease in MFa2 mRNA levels in our analysis. However, even though we have examined transcription of some of the same genes, our results differ from those of past studies. The discrepancies between the different studies may reflect differences in genetic backgrounds or, in some cases, a FIG. 5 . Overexpression of TFIIA suppresses spt3⌬. A wild-type strain (FY631), an spt3⌬ mutant (FY294), and an spt15-21 mutant (FY567) containing the insertion mutation lys2-173R2 were each transformed with the following high-copy-number plasmids: pRS426 (vector), pJM122 (TOA1 and TOA2 in pRS426), pSB238, (SUA7 in pRS426), pDE31-7 (SPT15 in pCGS42), and pFW32 (SPT3 in pCGS42). These strains were spotted on SC-Ura and replica plated to both SC-Ura-Lys and SC-Ura. This figure was produced by using Adobe Photoshop and a Fujix Pictography 3000 printer.
FIG. 6. Summary of the genetic interactions between mot1, toa1, and spt3⌬ mutations described in this study. The high-copy suppression specified between TOA1 and TOA2 of an spt3⌬ mutation specifically refers to TOA1 and TOA2 high-copy suppression of spt3⌬; SPT3 in high copy does not suppress toa1 mutants. a Viability or inviability of double mutants was tested by crossing the two single mutants, followed by tetrad analysis. In each cross, one of the two mutants also contained the cognate wild-type gene on a URA3 CEN plasmid. These putative double mutants were tested for the ability to lose the plasmid on 5-FOA. The plasmids used were pCC1 (SPT3 URA3 CEN) for mot1-24 spt3⌬ and toa1-18GSG spt3⌬ double mutants and pRS7.1BglII, (MOT1 URA3 CEN) for both mot1-24 spt3⌬ and mot1-24 toal-18GSG double mutants. In every cross performed we were able to monitor 2:2 segregation of each relevant marker, thus allowing positive identification of the double mutant progeny in every tetrad. The spt3⌬ mutation was scored by Spt Ϫ and Trp ϩ phenotypes and in some cases by PCR, the mot1-24 mutation was scored by a Ts Ϫ phenotype and by complementation, and the toa1-18GSG mutation was scored by a Ts Ϫ phenotype and by PCR. For the toa1-18GSG spt3⌬ cross, 15 tetrads were analyzed. For the other two synthetic lethal combinations, over 40 tetrads were analyzed for each combination. ϩ, viable (5-FOA resistant); Ϫ, inviable (5-FOA sensitive).
variation in results for a relatively small effect. Given the strong dependence of both Ty and HIS4 transcription on Mot1, our results strongly suggest that Mot1 functions to activate transcription, directly or indirectly, at certain promoters in vivo. Similar effects of mot1 mutations on transcript levels have also been observed recently in two other independent studies (11, 41a) .
In addition to genetic interactions between Mot1 and Spt3, we have demonstrated two types of genetic interactions between Spt3 and TFIIA: suppression of an spt3⌬ mutation by overexpression of TFIIA and synthetic lethality of spt3⌬ toa1 mutants. In addition, a toa1 mutation causes an Spt Ϫ phenotype. These results suggest that TFIIA and Spt3 might have similar or overlapping functions. Since TFIIA has been shown to stabilize TBP binding to DNA, a similar role seems likely for Spt3. In light of Spt3 being nonessential for growth and required only at certain promoters, its activity could be either to strengthen TFIIA function or to stabilized TBP-DNA interactions in a way independent of but additive with TFIIA. In either case, some as-yet-unrecognized promoter element or aspect of the TATA region must confer Spt3 dependence, either directly or indirectly.
Our results, taken together with past studies of Mot1 and Spt3, lead to a model in which Mot1, TFIIA, and Spt3 all contribute to transcriptional regulation by promoting TBP binding to functional TATA sequences (Fig. 7) . In this model, Mot1 acts indirectly, by preventing TBP from binding to nonfunctional TATA sequences, and TFIIA and Spt3 act directly to stabilize TBP on functional TATA sequences. We define a functional TATA box as a TATA sequence located in the context of a functional promoter. A nonfunctional TATA box would be a TATA sequence outside such a context; for example, at an inactive promoter or within the coding region of a gene. This model is consistent with the in vitro activities that have been demonstrated for both Mot1 and TFIIA. An additional consideration of this model is that Spt3 is required only at certain promoters. At Spt3-independent promoters, an Spt3-like activity may not be required, or other factors could work in a functionally similar fashion. One candidate for such a factor with Spt3-like activity is Fun81, the yeast protein that, like Spt3, shows similarity to human TAF II 18 (14, 38) . The mot1 effects that we have observed are promoter specific, since we detected no effect or very modest effects on transcript levels for six of eight genes examined. However, since MOT1 is essential, these defects likely represent only a subset of Mot1 activates in vivo. Future genetic analysis of other mot1 mutants should help clarify the in vivo activity of Mot1 and the specificity of its effects.
This model accounts for our molecular and genetic results in the following manner. First, mot1 mutations would lead to decreased transcription by allowing TBP to remain bound to nonfunctional TATA sequences, thus lowering the amount of TBP available for preinitiation complexes on functional TATA boxes. Similarly, if either positive factor, Spt3 or TFIIA, is mutant, then TBP would be less stably bound at a functional TATA box, also resulting in reduced transcription levels. In double mutants where two of these functions are defective, the ability of TBP to bind to functional TATA boxes is reduced below a critical threshhold required to maintain viability, resulting in the synthetic lethality that we have observed. In agreement with this model, overexpression of TFIIA exacerbates poor growth of mot1 mutants (34) . In this case we hypothesize that TFIIA is stabilizing TBP bound to nonfunctional TATA sequences. Our model relies on the assumption that the biochemical activity for Mot1 reflects its in vivo activity. Conceivably, other proteins could modify Mot1 activity in vivo such that it acts in a reverse direction, to promote stable TBP-DNA complexes. Such an activity would also be consistent with the decreased transcription we have observed in mot1 mutants.
Our model suggests possible biochemical interactions and activities for Spt3. We have tested extensively for several of these activities, and the results are summarized here. In many of these experiments we have used a glutathione S-transferaseSpt3 (GST-Spt3) fusion that has been purified from yeast and that is fully functional for Spt3 activity in vivo (34) . First, we assayed GST-Spt3 for the following TFIIA-like activities: the ability to supershift a TBP-DNA gel shift complex, the stabilization of a TBP-DNA gel shift complex under suboptimal magnesium conditions, and the ability to supershift a TBP-TFIIA-DNA gel shift complex. All of these results have been negative. Second, we have tested Spt3 for the ability to interact with Mot1 and TFIIA by both gel shift and coimmunoprecipitation; again, the results were negative. Finally, we have tested for the ability of GST-Spt3 to affect the activity of Mot1 in vitro. In this assay, Mot1 can supershift a TBP-DNA complex, and upon addition of ATP, the Mot1-TBP-DNA complex is disrupted (2, 3) . TFIIA has been shown to stabilize a TBP-DNA complex under these conditions. In the Mot1 assay, we have been unable to show that a GST-Spt3 fusion protein can stabilize a TBP-DNA complex in the presence of Mot1 and ATP. One possible explanation for our inability to demonstrate an activity for Spt3 in vitro is that other proteins or a certain promoter context may be required for the Spt3 activity. Two lines of evidence support this hypothesis. First, Spt3 sediments on glycerol gradients as if it was part of a large complex (48) . Second, mutations in other SPT genes, including SPT7 (20) , SPT8 (16) , and SPT20 (35, 49) , cause mutant phenotypes similar to those caused by spt3 and spt15 mutations, suggesting that the products encoded by these genes might be required for Spt3 activity.
In conclusion, our results suggest that Spt3, Mot1, and TFIIA are functionally related and that together they may control promoter-specific TBP binding. In contrast to previous analyses of Mot1 that suggested it represses transcription, our studies suggest that Mot1 may have a role in activating transcription in vivo. Conceivably, Mot1 could play roles in both activation and repression of transcription. Our studies have revealed a potential overlap in the in vivo function of TFIIA and Spt3, further suggesting that Spt3 may have a biochemical activity that helps specify some aspect of TBP binding to TATA boxes. Ultimately, a better understanding of the inter- VOL. 17, 1997 Spt3, Mot1, AND TFIIA GENETIC INTERACTIONSplay between Mot1, TFIIA, and Spt3 in the regulation of TBP function at both the biochemical and genetic levels should provide a more complete understanding of transcriptional control in vivo.
